These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35546739)

  • 1. Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody.
    Mizumaki K; Makino S; Ikawa Y; Maeda S; Horii M; Fushida N; Hamaguchi Y; Nohara T; Izumi K; Matsushita T
    J Dermatol; 2022 Sep; 49(9):e311-e312. PubMed ID: 35546739
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody".
    Koizumi H; Muro Y; Imai S; Yamashita Y; Ogawa-Momohara M; Takeichi T; Murakami M; Mitsuma T; Akiyama M
    J Dermatol; 2023 Jan; 50(1):e39-e40. PubMed ID: 36176040
    [No Abstract]   [Full Text] [Related]  

  • 3. A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
    Takatsuki K; Yanagihara T; Egashira A; Ogo N; Yoshizawa S; Sunami S; Asoh T; Maeyama T
    Am J Case Rep; 2021 Apr; 22():e930286. PubMed ID: 33903584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis.
    Kartolo A; Towheed T; Mates M
    Immunotherapy; 2021 Apr; 13(6):477-481. PubMed ID: 33626928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma.
    Yamaguchi Y; Aso M; Nagasawa H; Wada M
    Intern Med; 2021 Sep; 60(18):3025-3029. PubMed ID: 33776010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis.
    Dicaro D; Bowen C; Dalton SR
    J Am Acad Dermatol; 2014 Mar; 70(3):e64-5. PubMed ID: 24528921
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
    Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
    J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
    Kim Y; Park D; Choi SY; Chung C
    Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 11. Authors' reply to "a case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on the article by Mizumaki et al.".
    Matsushita T; Fushida N; Horii M; Mizumaki K
    J Dermatol; 2023 Jul; 50(7):e228-e229. PubMed ID: 36700524
    [No Abstract]   [Full Text] [Related]  

  • 12. Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis.
    Wu W; Chen J; Zhu L; Sha Y; Wang K; Zhao J; Ye C; Ye S
    Br J Dermatol; 2024 Jan; 190(2):285-287. PubMed ID: 37850872
    [No Abstract]   [Full Text] [Related]  

  • 13. Ulcerative Paraneoplastic Dermatomyositis in the Setting of Positive Transcriptional Intermediary Factor 1-γ Antibody.
    Al Awqati MZ; Sluzevich JC; Berianu F
    J Rheumatol; 2021 Aug; 48(8):1340. PubMed ID: 34329179
    [No Abstract]   [Full Text] [Related]  

  • 14. Triple carcinomas detected in two patients with anti-transcription intermediary factor 1γ (TIF1γ) antibody-positive dermatomyositis.
    Shimono M; Koike Y; Satomi N; Morisaki H; Ashida M; Murota H
    Eur J Dermatol; 2022 Apr; 32(2):285-287. PubMed ID: 35866906
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-TIF1-γ antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer.
    Li J; Yi S; Huang Y; Peng Y; Yang Z
    Clin Exp Rheumatol; 2023 Mar; 41(2):395. PubMed ID: 36622123
    [No Abstract]   [Full Text] [Related]  

  • 16. Case of dermatomyositis during treatment with pembrolizumab for lung cancer.
    Hinogami H; Yamashita C; Tanaka A; Shirai H; Nakano Y; Matsuura Y
    J Dermatol; 2019 Nov; 46(11):e430-e432. PubMed ID: 31215668
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
    Suga T; Oiwa H; Ishida M; Iwamoto Y
    Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
    Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
    Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
    Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
    Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
    Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
    Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.